Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.54−0.24 (-8.63%)
Close on Nov 18, 2026Market cap $21.18MP/E –Yield –
Evaxion A/S free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Evaxion A/S's free cash flow for the twelve months ending Jun 30, 2022 was -$24.56M. For fiscal 2025 it was -$6.64M. The highest annual figure on record is -$2.00M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.64M | – |
| FY2024 | Dec 31, 2024 | -$12.94M | – |
| FY2023 | Dec 31, 2023 | -$17.78M | – |
| FY2022 | Dec 31, 2022 | -$26.07M | – |
| FY2021 | Dec 31, 2021 | -$23.23M | – |
| FY2020 | Dec 31, 2020 | -$12.59M | – |
| FY2019 | Dec 31, 2019 | -$7.08M | – |
| FY2018 | Dec 31, 2018 | -$2.00M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | -$5.27M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.63M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.32M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.77M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.01M | – |
See a number that looks wrong?